Surrey Heartlands

Joint Formulary & PAD

Venlafaxine - Menopausal disorders

You are here : Home > Formulary Search > Venlafaxine - Menopausal disorders

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green (see narrative)
Formulations :
  • Modified release tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines
Off Label
SPC
Restrictions / Comments :
Important

Off-label use.

Documentation

Webpage
NICE NG23 menopause-diagnosis-and-management

PAD Profile

ChemicalSubstance :
Venlafaxine
Indication :
Menopausal disorders
Group Name :
Keywords :
Menopause, hot sweats, hot flushes, flushing, vasomotor symptoms, menopausal symptoms,
Brand Names Include :
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Menopausal disorders
Supporting Documents :
1

Other Indications

Below are listed other indications that Venlafaxine is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Menopausal disorders.

Committee Recommendations (2)

14 May 25 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The APC approved a change in Traffic Light Status from Blue to Green while reviewing drugs for inclusion on the Surrey Heartlands Joint Formulary.

It was agreed that GPs would initiate non-hormonal treatments for menopausal symptoms in accordance with CKS guidelines and NICE NG23: Menopause: identification and management

06 May 20 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The Surrey & North West Sussex Area Prescribing Committee updated their recommendations in line with NICE guidance NG23 Menopause diagnosis and management in May 2020.

Venlafaxine is recommended for menopausal symptoms and a BLUE (with no information sheet) traffic light status has been agreed. Please refer to the Menopause -NG23 briefing paper attached below for further information (Page 13/14). SNRIs should not be routinely offered as a first line treatment for vasomotor symptoms.